Persistent asthma: disease control, resource utilisation and direct costs

Abstract

Despite evidence that adverse outcomes are less frequent when asthma management is optimised, the link between the level of control, disease severity and medical resource utilisation (MRU) is poorly documented. This relationship was investigated in a group of patients suffering from persistent asthma (Global Initiative for Asthma (GINA) o2) in France.In 1998 a computerised family practice database was used to identify asthma patients aged 17-50 yrs. Information from the database was complemented by a patient survey to retrospectively assess the level of asthma control and hospital contacts. Costs of MRU over a 12-month study period were related to demographics, medical history, asthma control, and doses of inhaled corticosteroids prescribed during the prestudy period.A review of the computerised medical database identified 1,038 adult patients with persistent asthma, who completed the survey questionnaire. Over a 12-month period, the mean cost of MRU was 549.8 J for well-controlled patients, 746.3 J per patient with moderate control, and 1,451.3 J per patient with poor control. Costs also increased significantly with age, access to free asthma care, comorbid conditions, asthma symptoms in the past year and whether inhaled corticosteroids had been prescribed before the study period.In patients with persistent asthma, large differences were observed in the use of medical resources according to control and severity. Therefore, if patients appropriately use prescribed control therapy, their use of medical resources may be reduced. Eur Respir J 2002; 20: 260-267

Update on the roles of distal airways in asthma

“…Thirdly, severe asthma represents nearly 10% of all asthma cases, but up to 30% of the cost, which is mostly related to resource utilisation (e.g. unscheduled medical visits and hospitalisations) due to insufficient asthma control [5,6]. Taken together, these rather disappointing observations underscore the need for therapeutic improvement in asthma treatment.…”

Implementation of GINA guidelines in Ho Chi Minh City: a model for Viet Nam

“…1 The median direct health care cost in our study was lower than that reported in the United States (mean direct health care cost, US$3180) or in Europe (mean medical resource utilisation €549.8 for a controlled patient, and €1451.3 for a non-controlled patient). [21][22][23] The lower direct cost in HCMC was due to the inexpensive health care services, cheaper medications and lower hospitalisation rate when the patients used controllers. 3,13,24 The increased rate of controlled asthma in our study also contributed to the decrease in direct health care costs.…”

Direct costs of asthma in Brazil: a comparison between controlled and uncontrolled asthmatic patients

“…Indirect costs include costs resulting from missed work or school days and days with restricted activity at work, premature retirement and death. The adverse impact of asthma on the quality of life of the patients and on the families, as well as the limitation of physical, emotional and intellectual development is difficult to quantify, and therefore is referred to as intangible costs (8)(9)(10)(11)(12).…”